Korean Manufacturer Slapped With Warning Letter Over GMPs

Drug Industry Daily
A A
The FDA hit South Korean drugmaker Hanlim Pharma with a warning letter for current GMP and other deficiencies observed during an inspection of its OTC manufacturing facility in Gyeonggi-do province earlier this year.

To View This Article:

Login

Subscribe To Drug Industry Daily